Publication Date:
2009-11-20
Description:
Abstract 577 Introduction: Allogeneic SCT is currently the preferred therapeutic option for most younger adults with ALL in first complete remission (CR), as recently confirmed by the large ECOG-UKALL Intergroup study (Goldstone, Blood 2008). In this study, however, early response to therapy was not taken into account. As Ig/TCR MRD is one of the main determinants for outcome in childhood ALL, we analyzed its impact on outcome and SCT results in adults treated within pediatric-inspired GRAALL trials. For that purpose, we focused on early MRD evaluations (MRD1: at CR achievement; MDR2: after the first consolidation). Patients & Methods: Among 507 patients aged 15-60 years with Ph-negative ALL in first CR after induction included in the GRAALL-2003 (Huguet, JCO 2009) or in the ongoing GRAALL-2005 trial until the first planned interim analysis, 212 patients (B/T lineage, 137/75; median age, 31 years) had an Ig/TCR MDR1 evaluation (with MRD2 evaluation for 77% of them) by CDR3 RQ-PCR or fluorescent competitive Genescan associated with a sensitivity allowing the classification into the following levels: negative (0); positive
Print ISSN:
0006-4971
Electronic ISSN:
1528-0020
Topics:
Biology
,
Medicine
Permalink